Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...
Endo Reschedules Release of Fourth Quarter and Full Year 2024 Earnings Results and Conference Call
Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it has rescheduled the release of its fourth quarter and full year 2024 financial results to March 13, 2025, prior to market ...